about
E-cadherin's dark side: possible role in tumor progressionE-cadherin and gastric cancer: cause, consequence, and applicationsLevels of soluble E-cadherin in breast, gastric, and colorectal cancersCirculating cellular adhesion molecules and risk of diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA).Altered gene expression patterns during the initiation and promotion stages of neonatally diethylstilbestrol-induced hyperplasia/dysplasia/neoplasia in the hamster uterus.Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathwaysFragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of Helicobacter Pylori HtrA.Identification of E-cadherin signature motifs functioning as cleavage sites for Helicobacter pylori HtrAIdentification of a Novel Human E-Cadherin Splice Variant and Assessment of Its Effects Upon EMT-Related Events.RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR.Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer.Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesis.Modulation of RTK by sEcad: a putative mechanism for oncogenicity in oropharyngeal SCCs.Cooperative cell invasion: matrix metalloproteinase-mediated incorporation between cells.Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.Evidence for cadherin-11 cleavage in the synovium and partial characterization of its mechanism.sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-α production by interaction with its soluble E-cadherin ligand in chronically inflamed joints.Transferring the exudate in the tissue engineering chamber as a trigger to incubate large amount adipose tissue in remote area.Roles of RUNX in Hippo Pathway Signaling.
P2860
Q26865483-93580DCB-B06E-4E3A-A605-2538D8C8D16FQ27000278-6718607B-99B0-4630-B695-5B5B846CA862Q27012638-9B354B1E-4154-4837-8CE3-525E597F0A7EQ30277225-8865A09B-9B64-4294-92AE-6B62063B4E61Q34664105-25E7FA45-1A39-41E1-9147-281D0B29E737Q35133254-D048C7D5-A061-4AC9-BB6F-55A10939B8FDQ35662083-BEBA956B-5549-4791-8A0C-05136CCC4256Q35959929-0437EEAF-F279-48A6-A702-1BDE7AA5C393Q36147466-FC4E6D9B-1CB6-42DD-A49F-53C165A754CFQ36413997-BEDB0793-231C-4E60-94EC-C1540CB0A4A1Q36462450-8608AA2A-51DD-418C-A24F-785CC7C89918Q37428089-1B1167F7-DA3C-4F0A-BF85-18609612713CQ38679713-D2227594-478A-4A45-8393-8030DA4A16F8Q38907220-CB5360AE-DC57-4212-A28B-D9788FDFA403Q39017078-DC3A3754-5E11-42FB-87D1-0C7E54A470A6Q39411896-B7483719-9D9F-406B-818C-3362F00FAF4BQ40421665-7D8A41EF-AAF8-43C5-9E8D-EB14F08A5FD3Q41430438-1D5FFA49-B095-48B5-8841-1692F951C5B5Q41450346-A6356DC0-E214-4FB5-AEF8-17D80CDBB861Q41552639-88E95A55-7CD4-42C8-A0EE-67142A76A699Q44177491-C49C3084-A893-4288-B85F-705D42D118CCQ47607273-0E49F5CC-4492-4773-96D8-CC0FC5B10D71Q47944350-110DDF73-4D11-4725-B92B-57DFBFB66802
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Soluble E-cadherin: more than a symptom of disease.
@ast
Soluble E-cadherin: more than a symptom of disease.
@en
Soluble E-cadherin: more than a symptom of disease.
@nl
type
label
Soluble E-cadherin: more than a symptom of disease.
@ast
Soluble E-cadherin: more than a symptom of disease.
@en
Soluble E-cadherin: more than a symptom of disease.
@nl
prefLabel
Soluble E-cadherin: more than a symptom of disease.
@ast
Soluble E-cadherin: more than a symptom of disease.
@en
Soluble E-cadherin: more than a symptom of disease.
@nl
P2860
P356
P1476
Soluble E-cadherin: more than a symptom of disease
@en
P2093
Mark L Day
P2860
P304
P356
10.2741/4031
P577
2012-01-01T00:00:00Z